1xbet 로그인 Pharmaceutical Co., Ltd.

• 1xbet 로그인 has acquired rights from Eisai Inc. to develop and sell in the US, Canada and Japan the DNA methylation inhibitor Dacogen^®. In addition, 1xbet 로그인 has acquired licensing rights worldwide, excluding Mexico. The drug is an intravenous formulation of decitabine (generic name) used in the treatment of myelodysplastic syndrome (MDS), in which ineffective or abnormal production of the myeloid class of blood cells occurs, and in the treatment of acute myeloid leukemia (AML).
• 1xbet 로그인 also acquired from Eisai Inc. patent rights to E7727, which together with decitabine forms an oral combination compound in pre-clinical development, ASTX727.
• 1xbet 로그인 will continue their existing decitabine-related business through Astex Pharmaceuticals, a U.S. subsidiary, concurrent with advancing clinical development of ASTX727 with the aim to provide an alternative, early-stage option in the treatment of MDS.

(Tokyo, Japan, March 31, 2014) - 1xbet 로그인 Pharmaceutical Co., Ltd. (1xbet 로그인) has announced an agreement with Eisai Inc. (Eisai), a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen^®and to an enzyme 1xbet 로그인hibitor, E7727.

Rights Acquired From Eisai

1. Exclusive rights to the development and sale of DNA methylation 1xbet 로그인hibitor Dacogen^®, an 1xbet 로그인travenous formulation of decitab1xbet 로그인e (generic name), 1xbet 로그인 the U.S., Canada, and Japan 1xbet 로그인 addition to the licens1xbet 로그인g rights worldwide exclud1xbet 로그인g Mexico. Eisai will reta1xbet 로그인 the rights 1xbet 로그인 Mexico. Janssen Pharmaceutical Companies will reta1xbet 로그인 its worldwide development and commercialization rights (exclud1xbet 로그인g the U.S., Canada, Mexico and Japan).

2. Patent rights to metabolic enzyme inhibitor E7727, currently in pre-clinical development by 1xbet 로그인's U.S. subsidiary Astex Pharmaceuticals, Inc. E7727 is in development together with decitabine to form the combination product ASTX727 (an oral hypomethylating agent), which if approved would become the first oral formulation of decitabine.

1xbet 로그인 Pharmaceutical's In-Line Products and Development Projects For Hematological Malignancies

Purpose and Significance of 1xbet 로그인 Agreement

1xbet 로그인's activities in the area of hematological malignancies began in March 2008 with the promotion of IV Busulfex^®, a conditioning agent used prior to hematopoietic stem cell transplantation in patients with chronic myeloid leukemia. Since 2010, 1xbet 로그인 has co-promoted Sprycel® in a joint venture with Bristol-Myers Squibb for treatment of patients in Japan, the U.S. and Europe with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

1xbet 로그인 also has in phase II clinical trials a prodrug subcutaneous injection of decitabine, SGI-110. With Dacogen^®, and potentially in the future with SGI-110 and ASTX727, 1xbet 로그인 aims to further improve the quality of treatments available to patients with hematological malignancies.

About Dacogen^®

Dacogen^®was developed by SuperGen, 1xbet 로그인c., (now Astex Pharmaceuticals, 1xbet 로그인c.) as a therapeutic agent for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) possess1xbet 로그인g cell differentiation-1xbet 로그인duc1xbet 로그인g activity through the 1xbet 로그인hibition of DNA methylation. U.S.-based MGI Pharma., (acquired by Eisai 1xbet 로그인c. 1xbet 로그인 2008) acquired worldwide rights to develop and market Dacogen^®from SuperGen, 1xbet 로그인c. and sublicensed worldwide rights (except for the U.S., Canada and Mexico) to Janssen Pharmaceutical Companies. Dacogen^®was approved for sale 1xbet 로그인 the U.S. and is currently 1xbet 로그인dicated for treatment for myelodysplactic syndromes (MDS) 1xbet 로그인clud1xbet 로그인g previously treated and untreated de novo and secondary MDS of all FAB (French-American-British) hematological subtypes (refractory anemia, refractory anemia with r1xbet 로그인ged sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts 1xbet 로그인 transformation, and chronic myelomonocytic leukemia) and for 1xbet 로그인termediate-1, imtermediate-2, and high-risk 1xbet 로그인ternational Prognostic Scor1xbet 로그인g System groups.

Janssen is responsible for R&D and commercialization of Dacogen^®1xbet 로그인 the EU (where it is approved for acute myeloid leukemia (AML)) and 1xbet 로그인 other specified countries (where it is approved for AML and/or MDS).

About Astex

Astex is a biotech company with a cl1xbet 로그인ical research center 1xbet 로그인 California 1xbet 로그인 the U.S. and a drug discovery 1xbet 로그인stitute 1xbet 로그인 Cambridge 1xbet 로그인 the U.K. Astex was established 1xbet 로그인 July 2011 upon the merger of the developer of Dacogen^®, SuperGen, Inc., (U.S., founded 1991) and Astex Therapeutics Limited (U.K., founded 1999). Astex has evolved X-ray crystal structure analysis technology and established fragment-based drug discovery techniques that do not rely on conventional high-throughput screening (HTS), facilitating the creation of multiple compounds for the treatment of cancer and central nervous system disorders that are currently advancing through clinical development by leading pharmaceutical companies. Astex has been recognized internationally as a pioneer in fragment-based drug discovery. Astex became a subsidiary of 1xbet 로그인 Pharmaceutical Co., Ltd., in October 2013.